| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_71872d6f40adfb45b8a8731e75e2f43f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eec8878ed3b4fa03b284adc358831137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1bba710e7aaa56d8ab15a910fcd3dc5f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c38df77cfc0b02dcfc683a845e15484 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-335
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C235-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate |
2007-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_addd3db24e7aef63b37f20c4107b02f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e942dbbaae6333869f3f39d2f94ecf7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc1b86fb821396300273ddbcece3af24 |
| publicationDate |
2014-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8778985-B2 |
| titleOfInvention |
Inhibiting amyloid-beta peptide/rage interaction at the blood-brain barrier |
| abstract |
Small molecules are used to inhibit specific receptor-ligand interaction between Alzheimer's amyloid-β peptide (Aβ) and Receptor for Advanced Gly-cation Endproducts (RAGE). Objectives include treating Alzheimer's disease and other pathologies involving cerebral amyloid angiopathy; improving blood flow to or within the brain; decreasing the level of Aβ in the brain; reducing neuropathology associated with Alzheimer's disease; reducing inflammation and/or oxidant stress in the brain; improving memory and/or learning; treating other conditions involving Aβ/RAGE interaction at the blood-brain barrier, RAGE-mediated transport of Aβ into the brain, or RAGE activation in brain vasculature and/or brain parenchyma (e.g., diabetic complications); or any combination thereof. |
| priorityDate |
2006-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |